{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:57:39Z","timestamp":1791863859161,"version":"4.3.4"},"publisher-location":"Singapore","reference-count":81,"publisher":"Springer Nature Singapore","isbn-type":[{"value":"9789819568710","type":"print"},{"value":"9789819568727","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-981-95-6872-7_5","type":"book-chapter","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:21:42Z","timestamp":1777242102000},"page":"65-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rethinking the Treatment-Resistant Depression"],"prefix":"10.1007","author":[{"given":"Yunfei","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.neubiorev.2017.08.019","volume":"84","author":"H Akil","year":"2018","unstructured":"Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B et al (2018) Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev 84:272\u2013288","journal-title":"Neurosci Biobehav Rev"},{"key":"5_CR2","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2022.2353","volume":"66","author":"S Arjmand","year":"2023","unstructured":"Arjmand S, Grassi-Oliveira R, Wegener G (2023) Rethinking treatment-resistant depression to quasi-tenacious depression. Eur Psychiatry 66:e14","journal-title":"Eur Psychiatry"},{"key":"5_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.psc.2023.02.007","volume":"46","author":"ER Ayvaci","year":"2023","unstructured":"Ayvaci ER, Croarkin PE (2023) Special populations: treatment-resistant depression in children and adolescents. Psychiatr Clin North Am 46:359\u2013370","journal-title":"Psychiatr Clin North Am"},{"key":"5_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.172838","volume":"188","author":"DV Bavaresco","year":"2020","unstructured":"Bavaresco DV, Uggioni MLR, Ferraz SD, Marques RMM, Simon CS, Dagostin VS et al (2020) Efficacy of infliximab in treatment-resistant depression: a systematic review and meta-analysis. Pharmacol Biochem Behav 188:172838","journal-title":"Pharmacol Biochem Behav"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.encep.2018.02.001","volume":"45","author":"A Bourla","year":"2019","unstructured":"Bourla A, Chaneac E, Ferreri F (2019) Treatment-resistant depression and antidepressant plasma level: proposal of a pharmacogenetic-integrative algorithm from a case report. Enc\u00e9phale 45:92\u201394","journal-title":"Enc\u00e9phale"},{"key":"5_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-024-09554-x","volume":"51","author":"L Cai","year":"2024","unstructured":"Cai L, Xu J, Liu J, Luo H, Yang R, Gui X et al (2024) miRNAs in treatment-resistant depression: a systematic review. Mol Biol Rep 51:638","journal-title":"Mol Biol Rep"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/da.22705","volume":"35","author":"MS Cepeda","year":"2018","unstructured":"Cepeda MS, Reps J, Fife D, Blacketer C, Stang P, Ryan P (2018) Finding treatment-resistant depression in real-world data: how a data-driven approach compares with expert-based heuristics. Depress Anxiety 35:220\u2013228","journal-title":"Depress Anxiety"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/ijnp\/pyaa056","volume":"23","author":"MH Chen","year":"2020","unstructured":"Chen MH, Chang WC, Lin WC, Tu PC, Li CT, Bai YM et al (2020) Functional dysconnectivity of frontal cortex to striatum predicts ketamine infusion response in treatment-resistant depression. Int J Neuropsychopharmacol 23:791\u2013798","journal-title":"Int J Neuropsychopharmacol"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.psc.2023.02.010","volume":"46","author":"CR Chin Fatt","year":"2023","unstructured":"Chin Fatt CR, Mayes TL, Trivedi MH (2023) Immune dysregulation in treatment-resistant depression: precision approaches to treatment selection and development of novel treatments. Psychiatr Clin North Am 46:403\u2013413","journal-title":"Psychiatr Clin North Am"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1177\/02698811231171531","volume":"37","author":"N Chisamore","year":"2023","unstructured":"Chisamore N, Danayan K, Rodrigues NB, Di Vincenzo JD, Meshkat S, Doyle Z et al (2023) Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth. J Psychopharmacol 37:775\u2013783","journal-title":"J Psychopharmacol"},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1176\/appi.ajp.2019.19070720","volume":"177","author":"EJ Cole","year":"2020","unstructured":"Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C et al (2020) Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression. Am J Psychiatry 177:716\u2013726","journal-title":"Am J Psychiatry"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S2215-0366(20)30416-8","volume":"8","author":"L Cosgrove","year":"2021","unstructured":"Cosgrove L, Naudet F, Hogberg G, Shaughnessy AF, Cristea IA (2021) Reconceptualising treatment-resistant depression as difficult-to-treat depression. Lancet Psychiatry 8:11\u201313","journal-title":"Lancet Psychiatry"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/da.23193","volume":"38","author":"EJ Daly","year":"2021","unstructured":"Daly EJ, Turkoz I, Salvadore G, Fedgchin M, Ionescu DF, Starr HL et al (2021) The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. Depress Anxiety 38:1120\u20131130","journal-title":"Depress Anxiety"},{"key":"5_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115133","volume":"323","author":"K Danayan","year":"2023","unstructured":"Danayan K, Chisamore N, Rodrigues NB, Vincenzo JDD, Meshkat S, Doyle Z et al (2023) Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res 323:115133","journal-title":"Psychiatry Res"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ijnp\/pyy052","volume":"22","author":"K Demyttenaere","year":"2019","unstructured":"Demyttenaere K, Van Duppen Z (2019) The impact of (the concept of) treatment-resistant depression: an opinion review. Int J Neuropsychopharmacol 22:85\u201392","journal-title":"Int J Neuropsychopharmacol"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/s41380-025-02899-0","volume":"30","author":"C Fabbri","year":"2025","unstructured":"Fabbri C (2025) Treatment-resistant depression: role of genetic factors in the perspective of clinical stratification and treatment personalisation. Mol Psychiatry 30:2210\u20132218","journal-title":"Mol Psychiatry"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ijnp\/pyy024","volume":"22","author":"C Fabbri","year":"2019","unstructured":"Fabbri C, Corponi F, Souery D, Kasper S, Montgomery S, Zohar J et al (2019) The genetics of treatment-resistant depression: a critical review and future perspectives. Int J Neuropsychopharmacol 22:93\u2013104","journal-title":"Int J Neuropsychopharmacol"},{"key":"5_CR18","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852925000185","volume":"30","author":"S Fantasia","year":"2025","unstructured":"Fantasia S, Conti L, Andreoli D, Bordacchini A, Rimoldi B, Dell\u2019Oste V et al (2025) Early or recent trauma in treatment-resistant depression: a systematic review. CNS Spectr 30:e35","journal-title":"CNS Spectr"},{"key":"5_CR19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3758\/s13415-017-0544-6","volume":"17","author":"J Ferri","year":"2017","unstructured":"Ferri J, Eisendrath SJ, Fryer SL, Gillung E, Roach BJ, Mathalon DH (2017) Blunted amygdala activity is associated with depression severity in treatment-resistant depression. Cogn Affect Behav Neurosci 17:1221\u20131231","journal-title":"Cogn Affect Behav Neurosci"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/da.22968","volume":"37","author":"BN Gaynes","year":"2020","unstructured":"Gaynes BN, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J et al (2020) Defining treatment-resistant depression. Depress Anxiety 37:134\u2013145","journal-title":"Depress Anxiety"},{"key":"5_CR21","first-page":"1199","volume":"9","author":"K Goke","year":"2024","unstructured":"Goke K, McClintock SM, Mah L, Rajji TK, Lee HH, Nestor SM et al (2024) Cognitive profiles in treatment-resistant late-life depression and their impact on treatment outcomes. Biol Psychiatry Cogn Neurosci Neuroimag 9:1199\u20131210","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimag"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.psc.2023.02.009","volume":"46","author":"MM Grehl","year":"2023","unstructured":"Grehl MM, Hameed S, Murrough JW (2023) Brain features of treatment-resistant depression: a review of structural and functional connectivity magnetic resonance imaging studies. Psychiatr Clin North Am 46:391\u2013401","journal-title":"Psychiatr Clin North Am"},{"key":"5_CR23","doi-asserted-by":"publisher","unstructured":"Hashimoto K (2024) Are \u201cmystical experiences\u201d essential for antidepressant actions of ketamine and the classic psychedelics? Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-024-01770-7","DOI":"10.1007\/s00406-024-01770-7"},{"issue":"6747","key":"5_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1126\/science.adx4559","volume":"388","author":"K Hashimoto","year":"2025","unstructured":"Hashimoto K (2025) Extending ketamine\u2019s antidepressant effects. Science 388(6747):589\u2013590","journal-title":"Science"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jatmed.2024.07.001","volume":"3","author":"K Hashimoto","year":"2024","unstructured":"Hashimoto K, Zhao M, Zhu T, Wang X, Yang J (2024) Ketamine and its two enantiomers in anesthesiology and psychiatry: a historical review and future directions. J Anesth Transl Med 3:65\u201375","journal-title":"J Anesth Transl Med"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10578-016-0658-z","volume":"48","author":"KL Healy","year":"2017","unstructured":"Healy KL, Sanders MR (2017) Antecedents of treatment resistant depression in children victimized by peers. Child Psychiatry Hum Dev 48:107\u2013119","journal-title":"Child Psychiatry Hum Dev"},{"key":"5_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.31887\/DCNS.2018.20.1\/phenningsen","volume":"20","author":"P Henningsen","year":"2018","unstructured":"Henningsen P (2018) Management of somatic symptom disorder. Dialogues Clin Neurosci 20:23\u201331","journal-title":"Dialogues Clin Neurosci"},{"key":"5_CR28","first-page":"CD010558","volume":"5","author":"S Ijaz","year":"2018","unstructured":"Ijaz S, Davies P, Williams CJ, Kessler D, Lewis G, Wiles N (2018) Psychological therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev 5:CD010558","journal-title":"Cochrane Database Syst Rev"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.biopsych.2014.09.011","volume":"78","author":"R Iorio","year":"2015","unstructured":"Iorio R (2015) Treatment-resistant depression and aquaporin-4 autoantibodies: is there a link? Biol Psychiatry 78:e1\u2013e2","journal-title":"Biol Psychiatry"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jpsychires.2021.06.039","volume":"141","author":"I Israel-Elgali","year":"2021","unstructured":"Israel-Elgali I, Hertzberg L, Shapira G, Segev A, Krieger I, Nitzan U et al (2021) Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy. J Psychiatr Res 141:92\u2013103","journal-title":"J Psychiatr Res"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jad.2018.06.045","volume":"242","author":"KM Johnston","year":"2019","unstructured":"Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S (2019) The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord 242:195\u2013210","journal-title":"J Affect Disord"},{"key":"5_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euroneuro.2022.02.001","volume":"58","author":"S Kasper","year":"2022","unstructured":"Kasper S (2022) Is treatment-resistant depression really resistant? Eur Neuropsychopharmacol 58:44\u201346","journal-title":"Eur Neuropsychopharmacol"},{"key":"5_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4088\/JCP.15m10381","volume":"78","author":"A Kautzky","year":"2017","unstructured":"Kautzky A, Baldinger-Melich P, Kranz GS, Vanicek T, Souery D, Montgomery S et al (2017) A new prediction model for evaluating treatment-resistant depression. J Clin Psychiatry 78:215\u2013222","journal-title":"J Clin Psychiatry"},{"key":"5_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12888-024-05703-5","volume":"24","author":"KP Kennedy","year":"2024","unstructured":"Kennedy KP (2024) Inappropriate study inclusion in meta-analysis of sham-controlled rTMS for treatment-resistant depression. BMC Psychiatry 24:247","journal-title":"BMC Psychiatry"},{"key":"5_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pnpbp.2016.03.009","volume":"70","author":"YK Kim","year":"2016","unstructured":"Kim YK, Na KS (2016) Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Prog Neuro-Psychopharmacol Biol Psychiatry 70:117\u2013126","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"5_CR1000","doi-asserted-by":"publisher","unstructured":"Kn\u00f6chel C, Alves G, Friedrichs B, Schneider B, Schmidt-Rechau A, Wenzler S, et al (2015) Treatment-resistant late-life depression: challenges and perspectives. Curr Neuropharmacol 13(5):577\u2013591. https:\/\/doi.org\/10.2174\/1570159x1305151013200032","DOI":"10.2174\/1570159x1305151013200032"},{"key":"5_CR36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1055\/s-0028-1094425","volume":"7","author":"HE Lehmann","year":"1974","unstructured":"Lehmann HE (1974) Therapy-resistant depressions\u2014a clinical classification. Pharmakopsychiatr Neuropsychopharmakol 7:156\u2013163","journal-title":"Pharmakopsychiatr Neuropsychopharmakol"},{"key":"5_CR37","first-page":"1","volume":"278","author":"CT Li","year":"2023","unstructured":"Li CT (2023) Overview of treatment-resistant depression. Prog Brain Res 278:1\u201323","journal-title":"Prog Brain Res"},{"key":"5_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01035-6","volume":"10","author":"QS Li","year":"2020","unstructured":"Li QS, Tian C, Hinds D, Me Research T (2020) Genome-wide association studies of antidepressant class response and treatment-resistant depression. Transl Psychiatry 10:360","journal-title":"Transl Psychiatry"},{"key":"5_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jad.2019.02.005","volume":"249","author":"L Liao","year":"2019","unstructured":"Liao L, Wu Z, Mellor D, Peng D, Zhang C, Xu J et al (2019) Subtypes of treatment-resistant depression determined by a latent class analysis in a Chinese clinical population. J Affect Disord 249:82\u201389","journal-title":"J Affect Disord"},{"key":"5_CR40","doi-asserted-by":"crossref","unstructured":"Liu X, Mukai Y, Furtek CI, Bortnichak EA, Liaw KL, Zhong W (2021) Epidemiology of treatment-resistant depression in the United States. J Clin Psychiatry 83(1):21m13964","DOI":"10.4088\/JCP.21m13964"},{"key":"5_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsgos.2025.100502","volume":"5","author":"CWH Lo","year":"2025","unstructured":"Lo CWH, Gillett AC, Iveson MH, Kamp M, Fabbri C, Wong WLE et al (2025) Antidepressant switching as a proxy phenotype for drug nonresponse: investigating clinical, demographic, and genetic characteristics. Biological Psychiatry Global Open Science 5:100502","journal-title":"Biological Psychiatry Global Open Science"},{"key":"5_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2022.3860","volume":"80","author":"J Lundberg","year":"2023","unstructured":"Lundberg J, Cars T, Loov SA, Soderling J, Sundstrom J, Tiihonen J et al (2023) Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study. JAMA Psychiatry 80:167\u2013175","journal-title":"JAMA Psychiatry"},{"key":"5_CR43","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/da.20884","volume":"28","author":"FT Maalouf","year":"2011","unstructured":"Maalouf FT, Atwi M, Brent DA (2011) Treatment-resistant depression in adolescents: review and updates on clinical management. Depress Anxiety 28:946\u2013954","journal-title":"Depress Anxiety"},{"key":"5_CR44","doi-asserted-by":"crossref","unstructured":"Maffioletti E, Carvalho Silva R, Bortolomasi M, Baune BT, Gennarelli M, Minelli A (2021) Molecular biomarkers of electroconvulsive therapy effects and clinical response: understanding the present to shape the future. Brain Sci 11(9):1120","DOI":"10.3390\/brainsci11091120"},{"key":"5_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/YCT.0000000000000583","volume":"35","author":"E Maffioletti","year":"2019","unstructured":"Maffioletti E, Gennarelli M, Gainelli G, Bocchio-Chiavetto L, Bortolomasi M, Minelli A (2019) BDNF genotype and baseline serum levels in relation to electroconvulsive therapy effectiveness in treatment-resistant depressed patients. J ECT 35:189\u2013194","journal-title":"J ECT"},{"key":"5_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/0004867419897829","volume":"54","author":"GS Malhi","year":"2020","unstructured":"Malhi GS, Bell E (2020) Make news: treatment-resistant depression\u2014an irreversible problem in need of a reversible solution? Aust N Z J Psychiatry 54:111\u2013113","journal-title":"Aust N Z J Psychiatry"},{"key":"5_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.psc.2023.02.002","volume":"46","author":"TL Mayes","year":"2023","unstructured":"Mayes TL, Deane AE, Aramburu H, Yagnik K, Trivedi MH (2023) Improving identification and treatment outcomes of treatment-resistant depression through measurement-based care. Psychiatr Clin North Am 46:227\u2013245","journal-title":"Psychiatr Clin North Am"},{"key":"5_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","volume":"156","author":"RS McIntyre","year":"2014","unstructured":"McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS et al (2014) Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 156:1\u20137","journal-title":"J Affect Disord"},{"key":"5_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11920-017-0855-x","volume":"19","author":"Medeiros da Frota","year":"2017","unstructured":"Medeiros da Frota, Ribeiro C, Riva-Posse P (2017) Use of ketamine in elderly patients with treatment-resistant depression. Curr Psychiatry Rep 19:107","journal-title":"Curr Psychiatry Rep"},{"key":"5_CR50","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.4088\/JCP.15m10511","volume":"78","author":"A Nakagawa","year":"2017","unstructured":"Nakagawa A, Mitsuda D, Sado M, Abe T, Fujisawa D, Kikuchi T et al (2017) Effectiveness of supplementary cognitive-behavioral therapy for pharmacotherapy-resistant depression: a randomized controlled trial. J Clin Psychiatry 78:1126\u20131135","journal-title":"J Clin Psychiatry"},{"key":"5_CR51","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jad.2018.11.038","volume":"245","author":"CH Ng","year":"2019","unstructured":"Ng CH, Kato T, Han C, Wang G, Trivedi M, Ramesh V et al (2019) Definition of treatment-resistant depression\u2014Asia Pacific perspectives. J Affect Disord 245:626\u2013636","journal-title":"J Affect Disord"},{"key":"5_CR52","doi-asserted-by":"publisher","first-page":"273","DOI":"10.24869\/psyd.2018.273","volume":"30","author":"JP Pandarakalam","year":"2018","unstructured":"Pandarakalam JP (2018) Challenges of treatment-resistant depression. Psychiatr Danub 30:273\u2013284","journal-title":"Psychiatr Danub"},{"key":"5_CR53","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1039856220908167","volume":"28","author":"G Parker","year":"2020","unstructured":"Parker G (2020) Pseudo-melancholia. Australas Psychiatry 28:339\u2013341","journal-title":"Australas Psychiatry"},{"key":"5_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-med-050423-095712","volume":"76","author":"E Richardson","year":"2025","unstructured":"Richardson E, Patterson R, Meltzer-Brody S, McClure R, Tow A (2025) Transformative therapies for depression: postpartum depression, major depressive disorder, and treatment-resistant depression. Annu Rev Med 76:81\u201393","journal-title":"Annu Rev Med"},{"key":"5_CR55","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00737-013-0366-7","volume":"16","author":"TK Robakis","year":"2013","unstructured":"Robakis TK, Williams KE (2013) Biologically based treatment approaches to the patient with resistant perinatal depression. Arch Womens Ment Health 16:343\u2013351","journal-title":"Arch Womens Ment Health"},{"key":"5_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.sleep.2018.12.010","volume":"56","author":"R Robillard","year":"2019","unstructured":"Robillard R, Chase T, Courtney D, Ward M, De Koninck J, Lee EK (2019) Sleep-related breathing disturbances in adolescents with treatment resistant depression. Sleep Med 56:47\u201351","journal-title":"Sleep Med"},{"key":"5_CR57","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.psc.2023.02.006","volume":"46","author":"T Rogan","year":"2023","unstructured":"Rogan T, Wilkinson ST (2023) The role of psychotherapy in the management of treatment-resistant depression. Psychiatr Clin North Am 46:349\u2013358","journal-title":"Psychiatr Clin North Am"},{"key":"5_CR1001","doi-asserted-by":"publisher","unstructured":"Roose SP, Brown PJ (2022) What we know, what we do not know, and what we may know soon about interventions for treatment resistant depression in late-life? Am J Geriatr Psychiatry 30(5):557\u2013559. https:\/\/doi.org\/10.1016\/j.jagp.2021.10.009","DOI":"10.1016\/j.jagp.2021.10.009"},{"key":"5_CR58","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1176\/ajp.140.9.1159","volume":"140","author":"SP Roose","year":"1983","unstructured":"Roose SP, Glassman AH, Walsh BT, Woodring S, Vital-Herne J (1983) Depression, delusions, and suicide. Am J Psychiatry 140:1159\u20131162","journal-title":"Am J Psychiatry"},{"key":"5_CR59","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2174\/1570159X13666150630175044","volume":"13","author":"JD Rosenblat","year":"2015","unstructured":"Rosenblat JD, McIntyre RS, Alves GS, Fountoulakis KN, Carvalho AF (2015) Beyond monoamines-novel targets for treatment-resistant depression: a comprehensive review. Curr Neuropharmacol 13:636\u2013655","journal-title":"Curr Neuropharmacol"},{"key":"5_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jad.2011.02.020","volume":"137","author":"HG Ruhe","year":"2012","unstructured":"Ruhe HG, van Rooijen G, Spijker J, Peeters FP, Schene AH (2012) Staging methods for treatment resistant depression. A systematic review. J Affect Disord 137:35\u201345","journal-title":"J Affect Disord"},{"key":"5_CR61","doi-asserted-by":"crossref","unstructured":"Salloum NC, Papakostas GI (2019) Staging treatment intensity and defining resistant depression: historical overview and future directions. J Clin Psychiatry 80(4):18r12250","DOI":"10.4088\/JCP.18r12250"},{"key":"5_CR62","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/0269881111431748","volume":"26","author":"TE Schlaepfer","year":"2012","unstructured":"Schlaepfer TE, Agren H, Monteleone P, Gasto C, Pitchot W, Rouillon F et al (2012) The hidden third: improving outcome in treatment-resistant depression. J Psychopharmacol 26:587\u2013602","journal-title":"J Psychopharmacol"},{"key":"5_CR63","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2174\/1871527316666170413110605","volume":"16","author":"G Serafini","year":"2017","unstructured":"Serafini G, Adavastro G, Canepa G, Capobianco L, Conigliaro C, Pittaluga F et al (2017) Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and suicidality: a systematic review. CNS Neurol Disord Drug Targets 16:440\u2013453","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"5_CR64","doi-asserted-by":"crossref","unstructured":"Silberman EK, Weiss KJ (2016) Treatment-resistant depression or misdiagnosed anxiety disorder? J Nerv Ment Dis 204(1):67","DOI":"10.1097\/NMD.0000000000000409"},{"key":"5_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110268","volume":"144","author":"J Slupski","year":"2020","unstructured":"Slupski J, Cubala WJ, Gorska N, Slupska A, Galuszko-Wegielnik M (2020) Copper and anti-anhedonic effect of ketamine in treatment-resistant depression. Med Hypotheses 144:110268","journal-title":"Med Hypotheses"},{"key":"5_CR66","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jad.2016.01.004","volume":"193","author":"LH Souza","year":"2016","unstructured":"Souza LH, Salum GA, Mosqueiro BP, Caldieraro MA, Guerra TA, Fleck MP (2016) Interpersonal psychotherapy as add-on for treatment-resistant depression: a pragmatic randomized controlled trial. J Affect Disord 193:373\u2013380","journal-title":"J Affect Disord"},{"key":"5_CR67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1192\/bjp.2018.233","volume":"214","author":"R Strawbridge","year":"2019","unstructured":"Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL et al (2019) Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry 214:42\u201351","journal-title":"Br J Psychiatry"},{"key":"5_CR68","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.psc.2023.02.008","volume":"46","author":"S Subramanian","year":"2023","unstructured":"Subramanian S, Oughli HA, Gebara MA, Palanca BJA, Lenze EJ (2023) Treatment-resistant late-life depression: a review of clinical features, neuropsychology, neurobiology, and treatment. Psychiatr Clin North Am 46:371\u2013389","journal-title":"Psychiatr Clin North Am"},{"key":"5_CR69","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12888-022-04115-7","volume":"22","author":"H Taipale","year":"2022","unstructured":"Taipale H, Lahteenvuo M, Tanskanen A, Huoponen S, Rannanpaa S, Tiihonen J (2022) Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland\u2014a matched cohort study. BMC Psychiatry 22:484","journal-title":"BMC Psychiatry"},{"issue":"Suppl 13","key":"5_CR70","first-page":"23","volume":"58","author":"ME Thase","year":"1997","unstructured":"Thase ME, Rush AJ (1997) When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58(Suppl 13):23\u201329","journal-title":"J Clin Psychiatry"},{"key":"5_CR71","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/104012371402600310","volume":"26","author":"K Trevino","year":"2014","unstructured":"Trevino K, McClintock SM, McDonald Fischer N, Vora A, Husain MM (2014) Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry 26:222\u2013232","journal-title":"Ann Clin Psychiatry"},{"key":"5_CR72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S2215-0366(22)00002-5","volume":"9","author":"D Vigo","year":"2022","unstructured":"Vigo D, Jones L, Atun R, Thornicroft G (2022) The true global disease burden of mental illness: still elusive. Lancet Psychiatry 9:98\u2013100","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"5_CR73","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.biopsych.2014.06.021","volume":"77","author":"JJ Yang","year":"2015","unstructured":"Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K (2015) Serum interleukin-6 is a predictive biomarker for ketamine\u2019s antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 77(3):e19\u2013e20","journal-title":"Biol Psychiatry"},{"key":"5_CR74","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/bs.pbr.2023.03.003","volume":"278","author":"KC Yang","year":"2023","unstructured":"Yang KC, Chou YH (2023) Molecular imaging findings for treatment resistant depression. Prog Brain Res 278:79\u2013116","journal-title":"Prog Brain Res"},{"key":"5_CR75","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1080\/14656566.2021.1951225","volume":"22","author":"M Yavi","year":"2021","unstructured":"Yavi M, Henter ID, Park LT, Zarate C (2021) Key considerations in the pharmacological management of treatment-resistant depression. Expert Opin Pharmacother 22:2405\u20132415","journal-title":"Expert Opin Pharmacother"},{"key":"5_CR76","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.psc.2018.01.003","volume":"41","author":"M Young","year":"2018","unstructured":"Young M (2018) Treatment-resistant depression: the importance of identifying and treating co-occurring personality disorders. Psychiatr Clin North Am 41:249\u2013261","journal-title":"Psychiatr Clin North Am"},{"key":"5_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116092","volume":"340","author":"JY Yun","year":"2024","unstructured":"Yun JY, Kim YK (2024) Neural correlates of treatment response to ketamine for treatment-resistant depression: a systematic review of MRI-based studies. Psychiatry Res 340:116092","journal-title":"Psychiatry Res"},{"key":"5_CR78","doi-asserted-by":"crossref","unstructured":"Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P et al (2021) The prevalence and national burden of treatmentresistant depression and major depressive disorder in the United States. J Clin Psychiatry 82(2):20m13699","DOI":"10.4088\/JCP.20m13699"},{"key":"5_CR79","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.4088\/JCP.14r09204","volume":"76","author":"X Zhou","year":"2015","unstructured":"Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M et al (2015) Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 76:e487\u2013e498","journal-title":"J Clin Psychiatry"}],"container-title":["Advances in Experimental Medicine and Biology","Understanding Depression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-95-6872-7_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:21:44Z","timestamp":1777242104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-95-6872-7_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9789819568710","9789819568727"],"references-count":81,"URL":"https:\/\/doi.org\/10.1007\/978-981-95-6872-7_5","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 April 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declares the following as potential competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The author(s) declares that this manuscript does not include primary research with human participants.The author(s) declares that this manuscript does not include primary studies involving animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}